- Home
- AGL vs XNCR Comparison
AGL vs XNCR Comparison
Compare AGL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- XNCR
- Stock Information
- Founded
- AGL 2016
- XNCR 1997
- Country
- AGL United States
- XNCR United States
- Employees
- AGL N/A
- XNCR N/A
- Industry
- AGL Managed Health Care
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- XNCR Health Care
- Exchange
- AGL Nasdaq
- XNCR Nasdaq
- Market Cap
- AGL 1.4B
- XNCR 1.3B
- IPO Year
- AGL 2021
- XNCR 2013
- Fundamental
- Price
- AGL $3.53
- XNCR $15.74
- Analyst Decision
- AGL Hold
- XNCR Strong Buy
- Analyst Count
- AGL 18
- XNCR 8
- Target Price
- AGL $4.03
- XNCR $34.63
- AVG Volume (30 Days)
- AGL 5.1M
- XNCR 455.5K
- Earning Date
- AGL 02-25-2025
- XNCR 03-04-2025
- Dividend Yield
- AGL N/A
- XNCR N/A
- EPS Growth
- AGL N/A
- XNCR N/A
- EPS
- AGL N/A
- XNCR N/A
- Revenue
- AGL $5,594,117,000.00
- XNCR $85,164,000.00
- Revenue This Year
- AGL $41.67
- XNCR N/A
- Revenue Next Year
- AGL $8.85
- XNCR $80.86
- P/E Ratio
- AGL N/A
- XNCR N/A
- Revenue Growth
- AGL 54.10
- XNCR N/A
- 52 Week Low
- AGL $1.50
- XNCR $15.31
- 52 Week High
- AGL $7.73
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- AGL 59.38
- XNCR 21.76
- Support Level
- AGL $3.32
- XNCR $15.53
- Resistance Level
- AGL $3.73
- XNCR $16.69
- Average True Range (ATR)
- AGL 0.24
- XNCR 0.76
- MACD
- AGL -0.03
- XNCR 0.04
- Stochastic Oscillator
- AGL 54.40
- XNCR 9.57
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.